
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is poised for significant growth due to its multi-cancer early detection test, strong revenue guidance and partnership with Epic Aura. With a conservative guidance and the potential for a positive response from the oncology community for ASCO data and FDA approval, GRAIL is well-positioned for success in an underpenetrated market. Additionally, its materiality and potential for future growth make it an attractive investment opportunity.
Bears say
GRAIL is facing challenges with its declining ASPs and increasing volumes, leading to lower than expected revenue. This can be attributed to the company's reliance on discounting programs to engage customers and the potential for a slowdown in the self-pay market. On the upside, the company has a strong cash position and is seeing growth in prescribers, but there are risks related to FDA approval and Medicare reimbursement that could impact growth.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares